NOKOMIS, Fla. -- (BUSINESS WIRE) -- Rainbow Coral Corp. (OTCBB: RBCC) President and CEO Patrick Brown issued the following open letter to shareholders this morning discussing the company’s success in 2012 and big plans for the future:
Thank you for helping to make 2012 a huge success for Rainbow Coral Corp. The coming year will be even better, and we’re looking forward to announcing some exciting news that we’re certain will generate buzz and boost shareholder value in 2013.
Before we reveal our big plans for the future, however, let’s take a look back at all we’ve accomplished in 2012—our first full year in business.
One of the most exciting developments this year was the deepening relationship between our company and Amarantus BioSciences. Amarantus is on the cutting edge of biotech innovations, and when our joint venture is finalized, we plan to move forward aggressively toward swift profitability.
Our first priority will be commercialization of Amarantus’ incredible new breakthrough, NuroPro. The test has already completed a Phase 1 human clinical trial. Initiating Phase 2 clinical studies will be tops on our agenda next year. Upon completing Phase 2, NuroPro could begin generating revenue through sales under the Clinical Laboratory Improvement Amendment (CLIA) certification.
Next up will be MANF, the groundbreaking new therapeutic protein that Amarantus is developing to treat Parkinson’s disease and traumatic brain injuries. As the world’s population ages and neurological disorders become more prevalent, this could become a major source of revenue for our company soon. Stay tuned.
As many of us are aware, the cure to deadly diseases such as Parkinson’s, Alzheimer’s, and others could be developed someday soon using new stem cell treatments now being investigated. Thanks to adult stem cell technology, the moral objections to stem cell research are beginning to disappear, indicating a bright future for medical breakthroughs.
This year, our joint venture partner Nano3D BioSciences (n3D) demonstrated the impressive potential of its magnetic-levitation cell culturing system known as the Bio-Assembler. The Bio-Assembler’s fusion of magnetic levitation and nanoparticle assembly technology allows it to produce accurate, 3D representations of in vivo tissues faster and easier than any other existing tools.
In 2013, the Bio-Assembler is slated to be put to use in high-profile cancer research at the University of Texas Health Science Center at Houston in the Texas Medical Center. As word spreads about the value this technology brings to stem cell research, we expect to see an explosion in interest from top-flight researchers around the world.
We look forward to your continued support as we plan a tremendous year for RBCC and our shareholders in 2013. The best is yet to come for this company as we strive to grow our business worldwide. Enjoy the holidays, and thank you for being a part of Rainbow Coral Corp.!
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [http://www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.